Online inquiry

IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ83MR)

This product GTTS-WQ83MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets KDR gene. The antibody can be applied in Breast Cancer, Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002253.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3791
UniProt ID P35968
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ83MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14572MR IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA aCD1919
GTTS-WQ14877MR IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-LIV1A
GTTS-WQ15129MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SYD985
GTTS-WQ4643MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986036
GTTS-WQ139MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ7965MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GX-17
GTTS-WQ2376MR IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 102
GTTS-WQ5803MR IVTScrip™ mRNA-Anti-CD40, CFZ-533(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CFZ-533
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW